{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:13:16Z","timestamp":1770336796620,"version":"3.49.0"},"reference-count":86,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Activated protein C (APC) resistance (APCR) is considered a risk factor of venous thromboembolism (VTE). The most common genetic disorder conferring APCR is a factor (F) V Leiden mutation, but many other factors are also implicated, such as other F5 mutations (e.g., FV Hong-Kong and FV Cambridge), protein S deficiency, elevated factor VIII, exogenous hormone use, pregnancy and postpartum, depending on how APCR is defined. Considering the large population affected, the detection of this phenotype is crucial. Two types of tests are currently available: clotting time-based assays (with several versions) and thrombin generation-based assays with the endogenous thrombin potential (ETP)-based assay. The purpose of this review is therefore to discuss the performances of these tests and the cases in which it would be appropriate to use one over the other. Initially, as APCR was thought to be solely related to the FV Leiden mutation, the objective was to obtain a 100% specific assay. Clotting-time based assays were thus specifically designed to detect this inherited condition. Later on, an APCR condition without a FV Leiden mutation was identified and highlighted as an independent risk factor of VTE. Therefore, the development of a less specific assay was needed and a global coagulation test was proposed, known as the ETP-based APCR assay. In light of the above, these tests should not be used for the same purpose. Clotting time-based assays should only be recommended as a screening test for the detection of FV mutations prior to confirmation by genetic testing. On the other hand, the ETP-based APC resistance assay, in addition to being able to detect any type of APCR, could be proposed as a global screening test as it assesses the entire coagulation process.<\/jats:p>","DOI":"10.1055\/s-0042-1753511","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T22:50:01Z","timestamp":1662159001000},"page":"680-689","source":"Crossref","is-referenced-by-count":11,"title":["Laboratory Testing for the Evaluation of Phenotypic Activated Protein C Resistance"],"prefix":"10.1055","volume":"48","author":[{"given":"Laure","family":"Morimont","sequence":"additional","affiliation":[{"name":"Department of Research, Qualiblood Sa, Namur, Belgium"},{"name":"Department of Pharmacy, Faculty of Medicine, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Donis","sequence":"additional","affiliation":[{"name":"Department of Research, Qualiblood Sa, Namur, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Bouvy","sequence":"additional","affiliation":[{"name":"Department of Research, Qualiblood Sa, Namur, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Mullier","sequence":"additional","affiliation":[{"name":"Hematology Laboratory, Namur Research Institute for Life Sciences (NARILIS), Namur Thrombosis and Hemostasis Center (NTHC), Universit\u00e9 Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Michel","family":"Dogn\u00e9","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Medicine, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Douxfils","sequence":"additional","affiliation":[{"name":"Department of Research, Qualiblood Sa, Namur, Belgium"},{"name":"Department of Pharmacy, Faculty of Medicine, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"issue":"S 01","key":"ref1","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1080\/10245330512331390195","article-title":"The importance of the protein C system in the pathogenesis of venous thrombosis","volume":"10","author":"B Dahlb\u00e4ck","year":"2005","journal-title":"Hematology"},{"issue":"15","key":"ref2","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1016\/j.febslet.2005.03.001","article-title":"The anticoagulant protein C pathway","volume":"579","author":"B Dahlb\u00e4ck","year":"2005","journal-title":"FEBS Lett"},{"issue":"S 03","key":"ref3","doi-asserted-by":"crossref","first-page":"26S","DOI":"10.1378\/chest.124.3_suppl.26S","article-title":"The protein C pathway","volume":"124","author":"C T Esmon","year":"2003","journal-title":"Chest"},{"issue":"08","key":"ref4","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1161\/01.ATV.0000134298.25489.92","article-title":"Thrombomodulin-protein C-EPCR system: integrated to regulate coagulation and inflammation","volume":"24","author":"M Van de Wouwer","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"ref5","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1182\/blood-2003-10-3578","article-title":"Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations","volume":"103","author":"E Castoldi","year":"2004","journal-title":"Blood"},{"issue":"03","key":"ref6","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1046\/j.1365-2141.2003.04443.x","article-title":"Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women","volume":"122","author":"G Tans","year":"2003","journal-title":"Br J Haematol"},{"issue":"08","key":"ref7","doi-asserted-by":"crossref","first-page":"643","DOI":"10.7326\/0003-4819-130-8-199904200-00004","article-title":"Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism","volume":"130","author":"F Rodeghiero","year":"1999","journal-title":"Ann Intern Med"},{"issue":"04","key":"ref8","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1182\/blood.V93.4.1271","article-title":"A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis","volume":"93","author":"M CH de Visser","year":"1999","journal-title":"Blood"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000315141","article-title":"Factor V is an anticoagulant cofactor for activated protein C during inactivation of factor Va","volume":"37","author":"T J Cramer","year":"2010","journal-title":"Pathophysiol Haemost Thromb"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/joim.1997.242.s740.1","article-title":"Resistance to activated protein C caused by the R506Q mutation in the gene for factor V is a common risk factor for venous thrombosis","volume":"740","author":"B Dahlbck","year":"1997","journal-title":"J Intern Med Suppl"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1477-9560-4-15","article-title":"Hereditary thrombophilia","volume":"4","author":"S Khan","year":"2006","journal-title":"Thromb J"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/GIM.0b013e3181faa0f2","article-title":"Factor V Leiden thrombophilia","volume":"13","author":"J L Kujovich","year":"2011","journal-title":"Genet Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/5584_2016_120","article-title":"Genetic risk factors in venous thromboembolism","volume":"906","author":"C Hotoleanu","year":"2017","journal-title":"Adv Exp Med Biol"},{"issue":"02","key":"ref14","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.cll.2009.03.002","article-title":"Laboratory evaluation of hypercoagulability","volume":"29","author":"B Khor","year":"2009","journal-title":"Clin Lab Med"},{"issue":"04","key":"ref15","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ajhg.2015.01.019","article-title":"Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism","volume":"96","author":"M Germain","year":"2015","journal-title":"Am J Hum Genet"},{"issue":"07","key":"ref16","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/jth.13339","article-title":"Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn ) associated with activated protein C resistance","volume":"14","author":"B Pezeshkpoor","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref17","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/jth.13357","article-title":"Better or worse than the original","volume":"14","author":"F Bernardi","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref18","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1182\/blood-2002-02-0343","article-title":"Functional characterization of recombinant FV Hong Kong and FV Cambridge","volume":"100","author":"E Norstr\u00f8m","year":"2002","journal-title":"Blood"},{"issue":"05","key":"ref19","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/jth.15274","article-title":"Severe thrombophilia in a factor V-deficient patient homozygous for the Ala2086Asp mutation (FV Besan\u00e7on)","volume":"19","author":"E Castoldi","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref20","first-page":"21","article-title":"APC resistance: what have we learned since 1993?","volume":"28","author":"B Dahlback","year":"2004","journal-title":"J Lab Med"},{"issue":"09","key":"ref21","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1182\/blood-2003-06-2092","article-title":"Functional characterization of factor V-Ile359Thr: a novel mutation associated with thrombosis","volume":"103","author":"M Steen","year":"2004","journal-title":"Blood"},{"issue":"15","key":"ref22","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2013-10-530089","article-title":"Novel FV mutation (W1920R, FVNara) associated with serious deep vein thrombosis and more potent APC resistance relative to FVLeiden","volume":"123","author":"K Nogami","year":"2014","journal-title":"Blood"},{"issue":"04","key":"ref23","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood.V90.4.1552","article-title":"A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype","volume":"90","author":"F Bernardi","year":"1997","journal-title":"Blood"},{"issue":"04","key":"ref24","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1055\/s-0037-1613866","article-title":"The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis","volume":"83","author":"M C de Visser","year":"2000","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref25","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1080\/AC.70.6.3120184","article-title":"Factor-V HR2 haplotype and thromboembolic disease","volume":"70","author":"A Aleksova","year":"2015","journal-title":"Acta Cardiol"},{"issue":"06","key":"ref26","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1111\/j.1365-2516.2008.01775.x","article-title":"Protein S deficiency: a clinical perspective","volume":"14","author":"M K ten Kate","year":"2008","journal-title":"Haemophilia"},{"issue":"10","key":"ref27","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1111\/jth.13071","article-title":"Elevated levels of factor VIII and subsequent risk of all-cause mortality: results from the MEGA follow-up study","volume":"13","author":"E S Yap","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref28","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2141.2012.09134.x","article-title":"Elevated factor VIII levels and risk of venous thrombosis","volume":"157","author":"P V Jenkins","year":"2012","journal-title":"Br J Haematol"},{"issue":"03","key":"ref29","first-page":"CD010813","article-title":"Combined oral contraceptives: venous thrombosis","author":"M de Bastos","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"04","key":"ref30","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.contraception.2016.06.010","article-title":"Impact of estrogen type on cardiovascular safety of combined oral contraceptives","volume":"94","author":"J Dinger","year":"2016","journal-title":"Contraception"},{"issue":"10","key":"ref31","doi-asserted-by":"crossref","first-page":"697","DOI":"10.7326\/0003-4819-143-10-200511150-00006","article-title":"Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study","volume":"143","author":"J A Heit","year":"2005","journal-title":"Ann Intern Med"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/S0140-6736(95)91928-7","article-title":"Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components","volume":"346","author":"H Jick","year":"1995","journal-title":"Lancet"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"b2890","DOI":"10.1136\/bmj.b2890","article-title":"Hormonal contraception and risk of venous thromboembolism: national follow-up study","volume":"339","author":"\u00d8 Lidegaard","year":"2009","journal-title":"BMJ"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/bmj.312.7023.83","article-title":"Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study","volume":"312","author":"W O Spitzer","year":"1996","journal-title":"BMJ"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"b2921","DOI":"10.1136\/bmj.b2921","article-title":"The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study","volume":"339","author":"A van Hylckama Vlieg","year":"2009","journal-title":"BMJ"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.thromres.2018.06.014","article-title":"Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: a systematic review and meta-analysis","volume":"168","author":"D Rovinski","year":"2018","journal-title":"Thromb Res"},{"issue":"08","key":"ref37","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1055\/s-0040-1714140","article-title":"Oral contraceptives and venous thromboembolism: focus on testing that may enable prediction and assessment of the risk","volume":"46","author":"J Douxfils","year":"2020","journal-title":"Semin Thromb Hemost"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"769187","DOI":"10.3389\/fendo.2021.769187","article-title":"Combined oral contraceptives and venous thromboembolism: review and perspective to mitigate the risk","volume":"12","author":"L Morimont","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"ref39","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1056\/NEJM198109103051104","article-title":"Oral contraceptives and cardiovascular disease (first of two parts)","volume":"305","author":"B V Stadel","year":"1981","journal-title":"N Engl J Med"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S0140-6736(77)90888-1","article-title":"Haemostatic, lipid, and blood-pressure profiles of women on oral contraceptives containing 50 microgram or 30 microgram oestrogen","volume":"2","author":"T W Meade","year":"1977","journal-title":"Lancet"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S0002-9378(87)80129-1","article-title":"Coagulation effects of oral contraception","volume":"157","author":"J Bonnar","year":"1987","journal-title":"Am J Obstet Gynecol"},{"issue":"19","key":"ref42","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1001\/jama.1976.03270200017021","article-title":"Estrogen-containing oral contraceptive agents. A basis for their thrombogenicity","volume":"236","author":"S Wessler","year":"1976","journal-title":"JAMA"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.thromres.2004.08.004","article-title":"Haemostatic changes in pregnancy","volume":"114","author":"B Brenner","year":"2004","journal-title":"Thromb Res"},{"issue":"03","key":"ref44","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1055\/s-0038-1653788","article-title":"Sensitivity to activated protein C; influence of oral contraceptives and sex","volume":"73","author":"C M Henkens","year":"1995","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref45","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1365-2141.1995.tb05323.x","article-title":"Resistance to activated protein C in healthy women taking oral contraceptives","volume":"91","author":"O Olivieri","year":"1995","journal-title":"Br J Haematol"},{"issue":"03","key":"ref47","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1073\/pnas.90.3.1004","article-title":"Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C","volume":"90","author":"B Dahlb\u00e4ck","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref48","first-page":"779","volume-title":"Activated Partial Thromboplastin Time","author":"M Roshal","year":"2019"},{"issue":"12","key":"ref49","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/ajh.23867","article-title":"Activated protein C resistance testing for factor V Leiden","volume":"89","author":"S Kadauke","year":"2014","journal-title":"Am J Hematol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"6","DOI":"10.21037\/aob.2020.02.06","article-title":"The changing face of activated protein C resistance testing\u2014a 10-year retrospective","volume":"5","author":"E Dean","year":"2020","journal-title":"Ann Blood"},{"issue":"03","key":"ref52","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1055\/s-0037-1614945","article-title":"Standardization of the APC resistance test. Effects of normalization of results by means of pooled normal plasma","volume":"79","author":"A Tripodi","year":"1998","journal-title":"Thromb Haemost"},{"issue":"09","key":"ref53","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1111\/jth.14532","article-title":"Recommendations for clinical laboratory testing of activated protein C resistance; communication from the SSC of the ISTH","volume":"17","author":"G W Moore","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"02","key":"ref54","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/s-0041-1732465","article-title":"Snake venoms in diagnostic hemostasis and thrombosis","volume":"48","author":"G W Moore","year":"2022","journal-title":"Semin Thromb Hemost"},{"issue":"06","key":"ref55","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1309\/T8AVVH7QWGL0QTF5","article-title":"Improved distinction of factor V wild-type and factor V Leiden using a novel prothrombin-based activated protein C resistance assay","volume":"122","author":"M Wilmer","year":"2004","journal-title":"Am J Clin Pathol"},{"issue":"07","key":"ref56","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/MBC.0b013e3282891e2f","article-title":"Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis","volume":"18","author":"G Gessoni","year":"2007","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"01","key":"ref57","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.thromres.2006.06.015","article-title":"Clinical evaluation of a new functional test for detection of activated protein C resistance (Pefakit APC-R Factor V Leiden) at two centers in Europe and the USA","volume":"119","author":"R Sch\u00f6ni","year":"2007","journal-title":"Thromb Res"},{"issue":"02","key":"ref58","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/ijlh.13378","article-title":"Limitations of a calibrated, quantitative APC-R assay under routine conditions","volume":"43","author":"P Jilma-Stohlawetz","year":"2021","journal-title":"Int J Lab Hematol"},{"issue":"03","key":"ref59","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1538-7836.2009.03711.x","article-title":"APC resistance: biological basis and acquired influences","volume":"8","author":"E Castoldi","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref60","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1309\/QCUUNRMVJY8MWPPL","article-title":"Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden","volume":"119","author":"L L Graf","year":"2003","journal-title":"Am J Clin Pathol"},{"issue":"07","key":"ref61","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1111\/j.1538-7836.2005.01430.x","article-title":"Determinants of the aPTT- and ETP-based APC sensitivity tests","volume":"3","author":"M C de Visser","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref62","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/00001721-199701000-00006","article-title":"Effect of activated protein C on thrombin generation and on the thrombin potential in plasma of normal and APC-resistant individuals","volume":"8","author":"G A Nicolaes","year":"1997","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"01","key":"ref63","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/s-0037-1613145","article-title":"Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test","volume":"88","author":"J Curvers","year":"2002","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref64","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1515\/cclm-2019-0471","article-title":"Validation and standardization of the ETP-based activated protein C resistance test for the clinical investigation of steroid contraceptives in women: an unmet clinical and regulatory need","volume":"58","author":"J Douxfils","year":"2020","journal-title":"Clin Chem Lab Med"},{"issue":"06","key":"ref65","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1160\/TH07-07-0439","article-title":"Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography","volume":"98","author":"S N Tchaikovski","year":"2007","journal-title":"Thromb Haemost"},{"issue":"01","key":"ref66","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000071636","article-title":"Calibrated automated thrombin generation measurement in clotting plasma","volume":"33","author":"H C Hemker","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"issue":"02","key":"ref67","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1160\/TH05-08-0582","article-title":"Protein S levels modulate the activated protein C resistance phenotype induced by elevated prothrombin levels","volume":"95","author":"J M Brugge","year":"2006","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref68","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.thromres.2009.11.012","article-title":"Standardisation of thrombin generation test\u2013which reference plasma for TGT? An international multicentre study","volume":"125","author":"Y Dargaud","year":"2010","journal-title":"Thromb Res"},{"issue":"02","key":"ref69","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2141.2007.06785.x","article-title":"Effect of standardization and normalization on imprecision of calibrated automated thrombography: an international multicentre study","volume":"139","author":"Y Dargaud","year":"2007","journal-title":"Br J Haematol"},{"issue":"12","key":"ref70","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1111\/jth.12012","article-title":"Preanalytic variables of thrombin generation: towards a standard procedure and validation of the method","volume":"10","author":"R Loeffen","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref71","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.thromres.2014.12.015","article-title":"Large external quality assessment survey on thrombin generation with CAT: further evidence for the usefulness of normalisation with an external reference plasma","volume":"136","author":"J Perrin","year":"2015","journal-title":"Thromb Res"},{"issue":"04","key":"ref72","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/jth.14745","article-title":"Proof of concept of a new scale for the harmonization and the standardization of the ETP-based APC resistance","volume":"18","author":"L Morimont","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref75","doi-asserted-by":"crossref","first-page":"e12612","DOI":"10.1002\/rth2.12612","article-title":"Interlaboratory variability of activated protein C resistance using the ETP-based APC resistance assay","volume":"5","author":"L Morimont","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"01","key":"ref76","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/ijlh.13703","article-title":"Study of in vitro thrombin generation after neutralization of heparin","volume":"44","author":"M Hardy","year":"2022","journal-title":"Int J Lab Hematol"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.thromres.2020.04.044","article-title":"Interference of DOAC stop and DOAC remove in the thrombin generation assay and coagulation assays","volume":"192","author":"T Monteyne","year":"2020","journal-title":"Thromb Res"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.thromres.2018.08.014","article-title":"Use of DOAC Stop for elimination of anticoagulants in the thrombin generation assay","volume":"170","author":"W F Kopatz","year":"2018","journal-title":"Thromb Res"},{"issue":"03","key":"ref79","doi-asserted-by":"crossref","first-page":"e12684","DOI":"10.1002\/rth2.12684","article-title":"Analytical performance of the endogenous thrombin potential-based activated protein C resistance assay on the automated ST Genesia system","volume":"6","author":"L Morimont","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"issue":"02","key":"ref80","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2141.2009.08022.x","article-title":"Clinical guidelines for testing for heritable thrombophilia","volume":"149","author":"T Baglin","year":"2010","journal-title":"Br J Haematol"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.thromres.2020.08.006","article-title":"Letter to the Editors-in-Chief in response to the article of Abou-Ismail, et al. entitled \u201cEstrogen and thrombosis: a bench to bedside review\u201d (Thrombosis Research 192 (2020) 40-51)","volume":"193","author":"L Morimont","year":"2020","journal-title":"Thromb Res"},{"issue":"07","key":"ref83","doi-asserted-by":"crossref","first-page":"e0182041","DOI":"10.1371\/journal.pone.0182041","article-title":"Risk prediction of developing venous thrombosis in combined oral contraceptive users","volume":"12","author":"A McDaid","year":"2017","journal-title":"PLoS One"},{"issue":"13","key":"ref84","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1001\/jama.292.13.1573","article-title":"Estrogen plus progestin and risk of venous thrombosis","volume":"292","author":"M Cushman","year":"2004","journal-title":"JAMA"},{"issue":"07","key":"ref85","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/archinte.166.7.772","article-title":"Venous thrombosis and conjugated equine estrogen in women without a uterus","volume":"166","author":"J D Curb","year":"2006","journal-title":"Arch Intern Med"},{"issue":"09","key":"ref86","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/archinte.163.9.1105","article-title":"Role of family history in identifying women with thrombophilia and higher risk of venous thromboembolism during oral contraception","volume":"163","author":"B Cosmi","year":"2003","journal-title":"Arch Intern Med"},{"issue":"05","key":"ref87","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/j.1538-7836.2010.03773.x","article-title":"Prothrombin G20210A carriers the genetic mutation and a history of venous thrombosis contributes to thrombin generation independently of factor II plasma levels","volume":"8","author":"G Lavigne-Lissalde","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref88","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.1016\/j.thromres.2012.03.009","article-title":"Clinical and biological factors that contribute to thrombin generation in prothrombin G20210A carriers: a case-control study in a single Thrombophilia Center","volume":"129","author":"A Marco","year":"2012","journal-title":"Thromb Res"},{"issue":"04","key":"ref89","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1160\/TH07-09-0581","article-title":"Influence of coagulation factors and tissue factor concentration on the thrombin generation test in plasma","volume":"99","author":"J Duchemin","year":"2008","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref90","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.thromres.2010.10.017","article-title":"Elevated factor VIII enhances thrombin generation in the presence of factor VIII-deficiency, factor XI-deficiency or fondaparinux","volume":"127","author":"F Szlam","year":"2011","journal-title":"Thromb Res"},{"issue":"03","key":"ref91","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bjhh.2017.03.009","article-title":"Thrombin generation assays for global evaluation of the hemostatic system: perspectives and limitations","volume":"39","author":"R CF Duarte","year":"2017","journal-title":"Rev Bras Hematol Hemoter"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0042-1753511.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T12:57:43Z","timestamp":1730811463000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0042-1753511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":86,"aliases":["10.1055\/s-0042-1758162"],"journal-issue":{"issue":"06","published-online":{"date-parts":[[2022,10,12]]},"published-print":{"date-parts":[[2022,9]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0042-1753511","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}